ExonHit Therapeutics, Phase 2 clinical trial of its therapeutic compound, EHT 0202, in patients with Alzheimer's disease

20 December 2007 - ExonHit Therapeutics, a drug and diagnostic discovery company, announced today that it has obtained a regulatory approval to initiate a Phase 2 clinical trial of its therapeutic compound, EHT 0202, in patients with Alzheimer's disease. EHT 0202 is a compound, with a novel mechanism of action, which has shown benefits on memory and neuronal loss... ExonHit's Press Release -